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Background
Current heart failure guidelines recommend insertion of
implantable cardiac defibrillators (ICD) for primary pre-
vention of sudden cardiac death (SCD) in patients whose
left ventricular ejection fraction is (LVEF) ≤ 35% on maxi-
mally tolerated medical therapy. However, the majority of
sudden cardiac death (SCD) in patients with heart failure
occurs in those with mild-moderate systolic heart failure
(LVEF 36%-50%) who currently do not qualify for an ICD.
At present, our tools to reliably risk stratify patients with
mild-moderate heart failure to predict the likelihood of
SCD are limited. Recent data however suggest that ventri-
cular scar and/or replacement fibrosis, reliably identified
on Cardiac Magnetic Resonance Imaging (CMR), forms a
substrate for malignant arrhythmia, thus potentially identi-
fying a group at increased risk of SCD. The primary aim
of the Cardiovascular Magnetic Resonance GUIDEd man-
agement of mild-moderate left ventricular systolic Heart
Failure (CMR GUIDE HF) trial is to test the hypothesis
that among patients with mild-moderate heart failure, a
routine CMR guided management strategy of implantable
defibrillator (ICD) insertion is superior to a conservative
strategy of standard care.
Methods
A multi-centre randomized control trial based in Aus-
tralia and Europe, enrolling 428 patients with mild to
moderate left ventricular systolic dysfunction, on opti-
mal heart failure therapy. Participants will be recruited
through heart failure clinics and echocardiography
databases to undergo CMR assessment for myocardial
scar and fibrosis. The study will have two arms: Firstly,
those with myocardial scar/fibrosis will be enrolled into
a prospective, blocked, randomized control trial to
receive either primary prophylaxis ICD therapy or an
implantable loop recorder (ILR). Secondly, a further 521
patients without scar/fibrosis will be enrolled into an
observational registry. Follow-up with be at 3, 6, 12, 24
and 36 months for the implant groups (ICD and ILR)
and at 12, 24 and 36 months for the registry group.
Results
The primary endpoint will be time to sudden cardiac
death, or syncopal ventricular arrhythmia during an
average 3-year follow-up. The secondary endpoints con-
sist of sudden cardiac death, syncopal ventricular
arrhythmia, all-cause mortality, quality of life assessed
by Minnesota Living with Heart Failure Questionnaire,
heart failure related hospitalizations and a cost utility
analysis.
Conclusions
This study will use CMR as a novel tool for risk strati-
fication by directly imaging the scar which forms a cri-
tical substrate for ventricular arrhythmia. The results of
this study will result in a highly significant advance in
knowledge in this field by providing new information
about the potential benefits of primary prevention ICD
in mild-moderate LV systolic dysfunction. If proven, it
would radically alter the way in which patients are
selected for ICD therapy.
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